Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
    McMahan, Katherine
    Wegmann, Frank
    Aid, Malika
    Sciacca, Michaela
    Liu, Jinyan
    Hachmann, Nicole P.
    Miller, Jessica
    Jacob-Dolan, Catherine
    Powers, Olivia
    Hope, David
    Wu, Cindy
    Pereira, Juliana
    Murdza, Tetyana
    Mazurek, Camille R.
    Hoyt, Amelia
    Boon, Adrianus C. M.
    Davis-Gardner, Meredith
    Suthar, Mehul S.
    Martinot, Amanda J.
    Boursiquot, Mona
    Cook, Anthony
    Pessaint, Laurent
    Lewis, Mark G.
    Andersen, Hanne
    Tolboom, Jeroen
    Serroyen, Jan
    Solforosi, Laura
    Costes, Lea M. M.
    Zahn, Roland C.
    Barouch, Dan H.
    NATURE, 2024, 626 (7998) : 385 - 391
  • [42] Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
    Katherine McMahan
    Frank Wegmann
    Malika Aid
    Michaela Sciacca
    Jinyan Liu
    Nicole P. Hachmann
    Jessica Miller
    Catherine Jacob-Dolan
    Olivia Powers
    David Hope
    Cindy Wu
    Juliana Pereira
    Tetyana Murdza
    Camille R. Mazurek
    Amelia Hoyt
    Adrianus C. M. Boon
    Meredith Davis-Gardner
    Mehul S. Suthar
    Amanda J. Martinot
    Mona Boursiquot
    Anthony Cook
    Laurent Pessaint
    Mark G. Lewis
    Hanne Andersen
    Jeroen Tolboom
    Jan Serroyen
    Laura Solforosi
    Lea M. M. Costes
    Roland C. Zahn
    Dan H. Barouch
    Nature, 2024, 626 : 385 - 391
  • [43] Is SARS-CoV-2 prior infection related with more adverse effects to mRNA vaccine in healthcare workers?
    Meno Garcia, Cristina
    Maroto Abellan, Cristina
    Mahillo Fernandez, Ignacio
    del Campo Balsa, Teresa
    SAFETY AND HEALTH AT WORK, 2022, 13 : S168 - S168
  • [44] Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2
    Konstantinidis, Theocharis G.
    Zisaki, Stavroula
    Mitroulis, Ioannis
    Konstantinidou, Eleni
    Kontekaki, Eftychia G.
    Romanidou, Gioulia
    Karvelas, Alexandros
    Nanousi, Ioanna
    Lazidis, Leonidas
    Cassimos, Dimitrios
    Tsigalou, Christina
    Martinis, Georges
    Panopoulou, Maria
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [45] Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Psichogiou, Mina
    Karabinis, Andreas
    Poulakou, Garyphallia
    Antoniadou, Anastasia
    Kotanidou, Anastasia
    Degiannis, Dimitrios
    Pavlopoulou, Ioanna D.
    Chaidaroglou, Antigoni
    Roussos, Sotirios
    Mastrogianni, Elpida
    Eliadi, Irene
    Basoulis, Dimitrios
    Petsios, Konstantinos
    Leontis, Konstantinos
    Kakalou, Eleni
    Protopapas, Konstantinos
    Jahaj, Edison
    Pratikaki, Maria
    Syrigos, Konstantinos N.
    Lagiou, Pagona
    Gogas, Helen
    Tsiodras, Sotirios
    Magiorkinis, Gkikas
    Paraskevis, Dimitrios
    Sypsa, Vana
    Hatzakis, Angelos
    VACCINES, 2021, 9 (09)
  • [46] The Case Against Delaying Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine Boosting Doses
    Bieniasz, Paul D.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : 1321 - 1323
  • [47] Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
    Liu, Xiaoqiang
    Li, Yuhua
    Wang, Zhongfang
    Cao, Shouchun
    Huang, Weijin
    Yuan, Lin
    Huang, Yi-Jiao
    Zheng, Yan
    Chen, Jingjing
    Ying, Bo
    Xiang, Zuoyun
    Shi, Jin
    Zhao, Jincun
    Huang, Zhen
    Qin, Cheng-Feng
    CELL RESEARCH, 2022, 32 (08) : 777 - 780
  • [48] Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
    Xiaoqiang Liu
    Yuhua Li
    Zhongfang Wang
    Shouchun Cao
    Weijin Huang
    Lin Yuan
    Yi-Jiao Huang
    Yan Zheng
    Jingjing Chen
    Bo Ying
    Zuoyun Xiang
    Jin Shi
    Jincun Zhao
    Zhen Huang
    Cheng-Feng Qin
    Cell Research, 2022, 32 : 777 - 780
  • [49] Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore
    Tu, Tian Ming
    Yi, Shen Jia
    Koh, Jasmine Shimin
    Saffari, Seyed Ehsan
    Hoe, Rebecca Hui Min
    Chen, Geraldine Jiangyan
    Chiew, Hui Jin
    Tham, Carol Huilian
    Seet, Christopher Ying Hao
    Yong, Ming Hui
    Yong, Kok Pin
    Hui, Andrew Che-Fai
    Fan, Bingwen Eugene
    Tan, Benjamin Yong-Qiang
    Quek, Amy May Lin
    Seet, Raymond Chee Seong
    Yeo, Leonard Leong Litt
    Tan, Kevin
    Thirugnanam, Umapathi N.
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [50] Inactivated vaccine for SARS-CoV-2
    Emma Risson
    Nature Reviews Immunology, 2020, 20 : 353 - 353